Pacira BioSciences, Inc.
$24.9
▼
-0.39%
2026-04-21 08:46:01
www.pacira.com
NMS: PCRX
Explore Pacira BioSciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.01 B
Current Price
$24.9
52W High / Low
$27.64 / $18.8
Stock P/E
143.33
Book Value
$16.86
Dividend Yield
—
ROCE
2.91%
ROE
0.96%
Face Value
—
EPS
$0.16
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
825
Beta
0.2
Debt / Equity
60.34
Current Ratio
4.54
Quick Ratio
3.28
Forward P/E
6.81
Price / Sales
1.41
Enterprise Value
$1.14 B
EV / EBITDA
9.19
EV / Revenue
1.57
Rating
None
Target Price
$28.71
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Canopy Growth Corporation | $1.2 | — | $709.79 M | — | -8.06% | -48.5% | $3.28 / $1.18 | $1.49 |
| 2. | BGM Group Ltd. | $0.36 | — | $59.42 M | — | -0.81% | -3.37% | $17.17 / $0.27 | $1.85 |
| 3. | Regencell Bioscience Holdings Limited | $29.09 | — | $13.89 B | — | -57.45% | -54.81% | $83.6 / $0.7 | $0.01 |
| 4. | Bausch Health Companies Inc. | $5.91 | 14.05 | $3.02 B | — | 9.85% | 4.36% | $11.97 / $6.06 | $-1.5 |
| 5. | Amneal Pharmaceuticals, Inc. | $13.26 | 58.7 | $4.23 B | — | 14.23% | -80.04% | $15.42 / $7.01 | $-0.23 |
| 6. | Kiniksa Pharmaceuticals International, plc | $42.46 | 55.07 | $3.25 B | — | 12.37% | 11.73% | $50.03 / $19.62 | $7.44 |
| 7. | Talphera, Inc. | $0.78 | — | $40.17 M | — | -52.04% | -1.15% | $1.57 / $0.38 | $0.34 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 196.87 M | 179.52 M | 181.1 M | 168.92 M | 187.25 M | — |
| Operating Profit | 3.19 M | 13.15 M | 9.13 M | 8.18 M | 29.53 M | — |
| Net Profit | 1.64 M | 5.43 M | -4.85 M | 4.81 M | 16.04 M | — |
| EPS in Rs | 0.04 | 0.13 | -0.12 | 0.12 | 0.4 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 726.41 M | 700.97 M | 674.98 M | 666.82 M |
| Operating Profit | 33.3 M | 97.57 M | 87.32 M | 70.93 M |
| Net Profit | 7.03 M | -99.56 M | 41.95 M | 15.91 M |
| EPS in Rs | 0.17 | -2.46 | 1.04 | 0.39 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.26 B | 1.55 B | 1.57 B | 1.68 B |
| Total Liabilities | 571.81 M | 775.17 M | 704.26 M | 906.19 M |
| Equity | 693.11 M | 778.35 M | 870.13 M | 775.01 M |
| Current Assets | 547.97 M | 745.13 M | 509.99 M | 498.33 M |
| Current Liabilities | 120.59 M | 309.92 M | 97.38 M | 147.77 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 151.99 M | 189.39 M | 154.65 M | 145.27 M |
| Investing CF | 99.48 M | -83.28 M | 77.54 M | -225.19 M |
| Financing CF | -369.63 M | 17.36 M | -183.03 M | -401.53 M |
| Free CF | 136.66 M | 178.75 M | 139.49 M | 115.2 M |
| Capex | -15.33 M | -10.64 M | -15.16 M | -30.08 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 3.63% | 3.85% | 1.22% | — |
| Earnings Growth % | 107.07% | -337.3% | 163.72% | — |
| Profit Margin % | 0.97% | -14.2% | 6.22% | 2.39% |
| Operating Margin % | 4.58% | 13.92% | 12.94% | 10.64% |
| Gross Margin % | 79.39% | 75.69% | 72.64% | 70.11% |
| EBITDA Margin % | 16.86% | 4.15% | 22.9% | 21.05% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.